Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2093]
News [6483]
Articles [133]
Editorials [5]
Conferences [171]
elearning [10]
Lenalidomide with CD19 antibodies in L-MIND
Dr Kami Maddocks - Ohio State University, Columbus, USA
Lenalidomide with CD19 antibodies in L-MIND ( Dr Kami Maddocks - Ohio State University, Columbus, USA )
25 Jun 2017
Extended followup indicates daratumumab with bortezomib and dexamethasone for...
Prof Katja Weisel - University of Tübingen, Tübingen, Germany
Extended followup indicates daratumumab with bortezomib and dexamethasone for relapsed MM ( Prof Katja Weisel - University of Tübingen, Tübingen, Germany )
24 Jun 2017
Impact of mutational profile at diagnosis for MDS/CML
Dr Guillermo Montalban Bravo - MD Anderson Cancer Center, Houston, USA
Impact of mutational profile at diagnosis for MDS/CML ( Dr Guillermo Montalban Bravo - MD Anderson Cancer Center, Houston, USA )
24 Jun 2017
Triplet therapy for all comers in the CLL-BAG trial
Dr Paula Cramer – University of Cologne, Cologne, Germany
Triplet therapy for all comers in the CLL-BAG trial ( Dr Paula Cramer – University of Cologne, Cologne, Germany )
24 Jun 2017
Disruption of BAFF-BCR crosstalk in CLL
Dr Alexey Danilov - Knight Cancer Institute, Portland, USA
Disruption of BAFF-BCR crosstalk in CLL ( Dr Alexey Danilov - Knight Cancer Institute, Portland, USA )
24 Jun 2017
FDG-PET guidance allows substantial chemoreduction in Hodgkin lymphoma
Dr Peter Borchmann - Uniklinik Koeln, Cologne, Germany
FDG-PET guidance allows substantial chemoreduction in Hodgkin lymphoma ( Dr Peter Borchmann - Uniklinik Koeln, Cologne, Germany )
24 Jun 2017
Risk and benefit of anti-coagulants for elderly patients with cancer-associated...
Dr Alejandro Lazo-Langner - Department of Medicine, Western University, London...
Risk and benefit of anti-coagulants for elderly patients with cancer-associated venous thromboembolism ( Dr Alejandro Lazo-Langner - Department of Medicine, Western University, London, Ontario, Canada )
24 Jun 2017
Interim analysis of the JULIET study
Prof Gilles Salles - Université Claude Bernard, Lyon, France
Interim analysis of the JULIET study ( Prof Gilles Salles - Université Claude Bernard, Lyon, France )
24 Jun 2017
400mg imatinib as good as 800mg for 10 year CML survival
Prof Rüdiger Hehlmann - European LeukemiaNet, Mannheim, Germany
400mg imatinib as good as 800mg for 10 year CML survival ( Prof Rüdiger Hehlmann - European LeukemiaNet, Mannheim, Germany )
23 Jun 2017
Carfilzomib combinations in ENDEAVOR and FORTE
Prof Katja Weisel - University of Tübingen, Tübingen, Germany
Carfilzomib combinations in ENDEAVOR and FORTE ( Prof Katja Weisel - University of Tübingen, Tübingen, Germany )
23 Jun 2017
Dual JAK/SYK inhibition in refractory NHL with cerdulatinib
Dr Paul Hamlin - Memorial Sloan Kettering Cancer Center, NY, USA
Dual JAK/SYK inhibition in refractory NHL with cerdulatinib ( Dr Paul Hamlin - Memorial Sloan Kettering Cancer Center, NY, USA )
23 Jun 2017
Diverse T lymphocyte population fights leukaemia more effectively
Dr Michaela Kotrova - University Hospital Schleswig-Holstein, Kiel, Germany
Diverse T lymphocyte population fights leukaemia more effectively ( Dr Michaela Kotrova - University Hospital Schleswig-Holstein, Kiel, Germany )
23 Jun 2017

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation